表柔比星、吉西他滨联合奥沙利铂经导管肝动脉化疗栓塞介入治疗原发性肝癌的临床应用对比研究  

Comparative study on the clinical application of Epirubicin,gemcitabine combined with oxaliplatin in transcatheter hepatic arterial chemoembolization in the treatment of primary liver cancer

作　　者：曹海明 邱淑芳 李彬 张晗 Cao Hai-ming;Qiu Shu-fang;Li Bin;Zhang Han(Department of Radiological Intervention,Changge People's Hospital,Changge 461500,Henan,China;Department of Ultrasound,Changge People's Hospital,Changge 461500,Henan,China)

机构地区：[1]长葛市人民医院放射介入科,河南长葛461500 [2]长葛市人民医院超声科,河南长葛461500

出　　处：《四川生理科学杂志》2024年第1期212-214,共3页Sichuan Journal of Physiological Sciences

摘　　要：目的:研究表柔比星、吉西他滨联合奥沙利铂经导管肝动脉化疗栓塞介入治疗原发性肝癌的临床应用效果。方法:选取2021年1月至2023年1月期间我院收治的121例原发性肝癌患者作为研究对象,按照治疗方式分为对照组(n=56)和观察组(n=65)。对照组采用单纯的碘油栓塞瘤灶供血动脉治疗,观察组采用表柔比星、吉西他滨联合奥沙利铂经导管肝动脉化疗栓介入治疗。分析对比两组近期疗效、癌胚抗原(Carcinoembryonic antigen,CEA)和甲胎蛋白(Alpha fetoprotein,AFP)水平以及不良发应发生率。结果:治疗后,观察组的总有效率明显高于对照组(P<0.05);观察组血清中CEA和AFP均明显低于对照组(P<0.05);观察组不良反应总发生率明显低于对照组(P<0.05)。结论:表柔比星与吉西他滨联合奥沙利铂在经导管肝动脉介入化疗中应用,能有效改进临床治疗效果,使肿瘤标志物水平下降,衰减不良反应。Objective:To study the clinical efficacy of epirubicin,gemcitabine and oxaliplatin combined with transcatheter hepatic artery chemoembolization in the treatment of primary liver cancer.Methods:A total of 121 patients with primary liver cancer treated in our hospital from January 2021 to January 2023 were selected as research objects,and divided into control group(n=56)and observation group(n=65)according to treatment methods.The control group was treated with liodol embolization,while the observation group was treated with epirubicin,gemcitabine and oxaliplatin by transcatheter hepatic artery chemotherapy.The short-term efficacy,Carcinoembryonic antigen(CEA)and alpha-fetoprotein(AFP)levels and the incidence of adverse reactions were analyzed and compared between the two groups.Results:After treatment,the total effective rate of observation group was significantly higher than that of control group(P<0.05).Serum CEA and AFP levels in observation group were significantly lower than those in control group(P<0.05).The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:The application of epirubicin and gemcitabine combined with oxaliplatin in transcatheter hepatic arterial interventional chemotherapy can effectively improve the clinical therapeutic effect,reduce the level of tumor markers and attenuate adverse reactions.

关 键 词：表柔沙星 吉他西滨 奥沙利铂 肝动脉化疗 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]